Siklos 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
T/0057 
Transfer of Marketing Authorisation 
30/06/2023 
26/07/2023 
SmPC, 
Labelling and 
PL 
IA/0056 
B.II.b.4.a - Change in the batch size (including batch 
28/04/2023 
n/a 
size ranges) of the finished product - Up to 10-fold 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
compared to the originally approved batch size 
IAIN/0055 
A.1 - Administrative change - Change in the name 
27/01/2023 
04/04/2023 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
202206 
hydroxycarbamide (for centrally authorised product 
only) 
IA/0053 
B.III.1.a.2 - Submission of a new/updated or 
05/09/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
II/0051 
C.I.3.b  
22/04/2022 
04/04/2023 
SmPC 
SmPC new text 
Update of section 5.1 of the SmPC with the available 
paediatric data from the studies NOHARM and Escort 
HU according to the PAM-Leg 34. 
C.I.3.b - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Change(s) with 
new additional data submitted by the MAH 
The MAH has added text section 5.1 to summarize the 
paediatric data in children < 2 year old from the two 
randomised placebo-controlled clinical trials (BABY HUG 
and NOHARM) and subsequent cohort studies providing 
supporting efficacy and safety data (including data on the 
maximum tolerated dose). 
For more information, please refer to the Summary of 
Product Characteristics. 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
202106 
hydroxycarbamide (for centrally authorised product 
only) 
IB/0049 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
11/11/2021 
16/12/2021 
SmPC, 
intended to implement the outcome of a procedure 
Labelling and 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
PL 
II/0047 
Update of sections 4.8 and 5.1 of the SmPC to 
22/07/2021 
16/12/2021 
SmPC and PL 
Please refer to Scientific Discussion ‘Siklos-H-C-000689-II-
0047’ 
include relevant information in paediatric patients 
based on results from the uncontrolled study 
ESCORT HU. In addition, the Marketing authorisation 
holder (MAH) took the opportunity to update the list 
of local representatives for Croatia in the Package 
Leaflet. Furthermore, the PI is brought in line with 
the latest QRD template version 10.2.and some 
minor editorial changes are included. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
28/01/2021 
28/01/2021 
SmPC 
Refer to Scientific conclusions and grounds recommending 
202006 
hydroxycarbamide (for centrally authorised product 
the variation to terms of the Marketing Authorisation(s)’ for 
only) 
PSUSA/1692/202006. 
II/0045 
Update of sections 4.2, 4.4, 4.5, 4.6, 4.8, 4.9 and 
09/07/2020 
27/05/2021 
SmPC, Annex 
SmPC new text: 
5.1 of the SmPC as a consequence of the final study 
results of the non-interventional cohort study 
ESCORT-HU (European Sickle Cell Disease Cohort – 
Hydroxyurea) and harmonisation with other HU 
products. In addition, Annex II is amended to revise 
the information on the physician information pack 
and to add that pharmacists should receive targeted 
communication on the risk of medication error due to 
the confusion between the two strengths where both 
II and PL 
Sections 4.2 and 4.4: 
Additional changes include modification of the neutrophil 
count threshold requiring modification of treatment, 
modification of the frequency of blood count monitoring at 
initiation of treatment and removal of recommendation on 
continuous follow
up of the growth of treated children and 
adolescents.  
-
Section 4.6 
The figures for cases of pregnancy were updated to reflect 
Page 3/14 
 
 
 
 
 
 
 
 
 
are available. The PIL is updated in accordance with 
the changes to the SmPC. The RMP (v. 20 revision 1) 
is updated to reflect the finalisation of the ESCORT-
HU study and modifications on the risk minimisation 
measures. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
the data collected in ESCORT-HU without modifying the 
recommendation.  
Section 4.8 
The figures for cases of undesirable effects were updated to 
reflect the data collected in ESCORT-HU without modifying 
the recommendation.  
Section 4.9 
The figures for cases of overdose were updated to reflect 
the data collected in ESCORT-HU without modifying the 
recommendation.  
For more information, please refer to the Summary of 
Product Characteristics. 
IAIN/0046 
A.5.a - Administrative change - Change in the name 
29/05/2020 
27/05/2021 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC Recommendation - maintenance 
201906 
hydroxycarbamide (for centrally authorised product 
only) 
IA/0044/G 
This was an application for a group of variations. 
20/11/2019 
n/a 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.1.a.1 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
N/0042 
Minor change in labelling or package leaflet not 
29/07/2019 
27/05/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0041/G 
This was an application for a group of variations. 
20/03/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.8 - Administrative change - Changes to date of the 
audit to verify GMP compliance of the manufacturer 
of AS 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.2.a - Change in test procedure for the finished 
Page 5/14 
 
 
 
 
 
 
 
 
 
 
 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
17/01/2019 
n/a 
PRAC Recommendation - maintenance 
201806 
hydroxycarbamide (for centrally authorised product 
only) 
N/0040 
Minor change in labelling or package leaflet not 
28/11/2018 
27/05/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0038 
C.I.z - Changes (Safety/Efficacy) of Human and 
31/05/2018 
02/08/2018 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0036 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
02/03/2018 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
11/01/2018 
n/a 
PRAC Recommendation - maintenance 
201706 
hydroxycarbamide (for centrally authorised product 
only) 
IB/0035/G 
This was an application for a group of variations. 
17/11/2017 
02/08/2018 
SmPC, 
B.II.a.1.a - Change or addition of imprints, bossing 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
Labelling and 
PL 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.a.1.b - Change or addition of imprints, bossing 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
scoring/break lines intended to divide into equal 
doses 
B.II.a.2.a - Change in the shape or dimensions of the 
pharmaceutical form - Immediate release tablets, 
capsules, suppositories and pessaries 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
IAIN/0033 
B.II.a.1.a - Change or addition of imprints, bossing 
15/09/2017 
02/08/2018 
SmPC and PL 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
IAIN/0032/G 
This was an application for a group of variations. 
04/08/2017 
02/08/2018 
SmPC, 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Labelling and 
PL 
II/0031/G 
This was an application for a group of variations. 
18/05/2017 
n/a 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.1.g - Change in the specification parameters 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
R/0030 
Renewal of the marketing authorisation. 
23/02/2017 
24/04/2017 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of Siklos 
PL 
in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation, with unlimited validity. 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
12/01/2017 
n/a 
PRAC Recommendation - maintenance 
201606 
hydroxycarbamide (for centrally authorised product 
only) 
PSUSA/1692/
Periodic Safety Update EU Single assessment - 
14/01/2016 
n/a 
PRAC Recommendation - maintenance 
201506 
hydroxycarbamide (for centrally authorised product 
only) 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0026 
C.I.8.a - Introduction of or changes to a summary of 
11/08/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
PSUV/0025 
Periodic Safety Update 
09/01/2015 
n/a 
PRAC Recommendation - maintenance 
N/0024 
Minor change in labelling or package leaflet not 
14/07/2014 
24/04/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUV/0020 
Periodic Safety Update 
20/02/2014 
23/04/2014 
SmPC and PL 
The frequency of azoospermia and oligospermia in the 
SmPC/PL should be changed from “very rare” to “very 
common”.  The proposed changes to sections 4.6 and 4.8 
of the SmPC and the leaflet are detailed in Annex 1 of the 
appended assessment report. However, a further update to 
the SmPC might be needed, if final study results become 
available in 2014. 
IB/0023 
B.II.b.5.z - Change to in-process tests or limits 
25/02/2014 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IAIN/0022 
C.I.9.b - Changes to an existing pharmacovigilance 
20/02/2014 
n/a 
system as described in the DDPS - Change(s) in the 
safety database and/or major contractual 
arrangements for the fulfilment of PhV obligations, 
and/or change of the site undergoing PhV activities 
IA/0021/G 
This was an application for a group of variations. 
19/02/2014 
n/a 
B.II.a.3.b.1 - Changes in the composition 
(excipients) of the finished product - Other excipients 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Any minor adjustment of the quantitative 
composition of the finished product with respect to 
excipients 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0019 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
12/10/2012 
23/04/2014 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
R/0018 
Renewal of the marketing authorisation. 
19/04/2012 
28/06/2012 
SmPC 
Based on the review of the available information the CHMP 
IA/0017/G 
This was an application for a group of variations. 
26/01/2012 
10/05/2012 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
is of the opinion that the quality, the safety and the efficacy 
of Siklos continues to be adequately and sufficiently 
demonstrated and considers that the benefit/risk profile of 
this medicinal product continues to be favourable. The 
CHMP recommends the renewal of the Marketing 
Authorisation for Siklos, subject to the conditions and 
obligations as laid down in Annex II to the Opinion. The 
CHMP recommends that the renewal be granted for a 
further 5 years. The MAH is requested to submit yearly 
PSURs unless otherwise specified by the CHMP. 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
B.II.b.3.a - Change in the manufacturing process of 
the finished product - Minor change in the 
manufacturing process of an immediate release solid 
oral dosage form or oral solutions 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter (e.g. deletion 
of an obsolete parameter 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0015 
- to replace the manufacturing site for the finished 
07/06/2011 
n/a 
product 
Page 11/14 
 
 
 
 
 
 
 
 
 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
N/0014 
Minor change in labelling or package leaflet not 
19/05/2011 
n/a 
Labelling and 
The MAH applied to delete some not legally required 
connected with the SPC (Art. 61.3 Notification) 
PL 
information in Annex IIIA, in order to accommodate the 
space problem raised by the trilingual labels. In addition, 
the Braille mentioned in the outer carton will be embossed 
in lower cases. Finally, additional minor linguistic changes 
have been proposed for DE, EL, ES, FR, MT, NL, PT and SK 
languages. 
IA/0016/G 
This was an application for a group of variations. 
11/05/2011 
n/a 
SmPC and PL 
B.II.a.1.a - Change or addition of imprints, bossing 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the currently approved batch size 
X/0005 
Annex I_2.(c) Change or addition of a new 
18/11/2010 
28/02/2011 
SmPC, 
strength/potency 
Labelling and 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
IA/0013 
B.II.b.2.b.2 - Change to batch release arrangements 
19/11/2010 
n/a 
Annex II and 
and quality control testing of the FP - Including batch 
PL 
control/testing 
PL 
IA/0012/G 
This was an application for a group of variations. 
26/10/2010 
n/a 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IA/0009 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
09/09/2010 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IB/0008/G 
This was an application for a group of variations. 
21/07/2010 
n/a 
SmPC, 
B.II.e.1.b.2 - Change in immediate packaging of the 
finished product - Type of container - Sterile 
medicinal products and biological/immunological 
medicinal products 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
B.II.b.1.a - Replacement or addition of a 
Labelling and 
PL 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
N/0007 
Minor change in labelling or package leaflet not 
21/05/2010 
n/a 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0006 
IA_01_Change in the name and/or address of the 
27/01/2010 
n/a 
SmPC, 
marketing authorisation holder 
Labelling and 
PL 
IA/0004 
IA_07_a_Replacement/add. of manufacturing site: 
05/05/2009 
n/a 
Secondary packaging site 
IA/0002 
IA_38_a_Change in test procedure of finished 
05/05/2009 
n/a 
product - minor change to approved test procedure 
II/0001 
Update of Detailed Description of the 
30/05/2008 
07/07/2008 
SmPC, Annex 
The MAH applied to update the Detailed Description of the 
Pharmacovigilance System 
II and Labelling 
Pharmacovigilance System further to a change in the 
Changes to QPPV 
Update of DDPS (Pharmacovigilance) 
management of the pharmacovigilance and of the Qualified 
Person for Pharmacovigilance (QPPV). Consequently, a new 
version of the risk Management plan has been issued to be 
signed by the new QPPV. Annex II has been updated using 
standard text and including the new version numbers of 
these documents. The marketing authorisation number was 
included in Annexes I and IIIA, as well as the date of first 
authorisation in Annex I. 
Page 14/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
